Drug Combo That Extends Survival Rate in Renal Cancer Tops SPT Week in Review

Top news of the week from Specialty Pharmacy Times.

5. FDA OKs New Treatment for Hemophilia A

Turoctocog alfa pegol, also known as N8-GP (Esperoct, Novo Nordisk), is indicated for adults and children with hemophilia A. Read More.

4. Secukinumab Demonstrates Quality of Life Improvements in Psoriasis Patients

Data from an analysis of multiple phase 3 studies highlight improvements in mobility, self-care, and usual activities for patients with moderate-to-severe psoriasis taking secukinumab (Cosentyx). Read more.

3. Preliminary Data Suggest Clinical Benefit of Investigational Glioblastoma Drug

MDNA55 prolonged survival in IL4R-positive patients with recurrent glioblastoma in a phase 2b clinical trial. Read more.

2. FDA Grants Priority Review to Keytruda, Inlyta Combo for Advanced Kidney Cancer

The sBLA is based on data showing significant improvement in overall survival and progression-free survival in patients with advanced renal cell carcinoma. Read More.

1. Pembrolizumab, Axitinib Combo Extends Survival in Advanced Renal Cancer Study

Pembrolizumab (Keytruda) plus axitinib (Inlyta) was evaluated in a clinical trial of patients with clear-cell metastatic renal cell carcinoma. Read More.